Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
|Articles|July 18, 2019
Supplements and Featured Publications
- Exclusive Coverage of the 2019 American Society of Clinical Oncology Annual Meeting
Exclusive Coverage of the 2019 American Society of Clinical Oncology Annual Meeting
Advertisement
Highlights from the 2019 American Society of Clinical Oncology Annual Meeting, which took place on May 31-June 4 in Chicago, IL are available in this newsletter published by The American Journal of Managed Care.
Advertisement
Related to this article
Boarding admitted patients on inpatient floor hallways can alleviate emergency department (ED) crowding. Outcomes tend to be positive, but the published evidence is weak, according to this systematic review.
Accelerated approvals, surrogate end points, and high drug costs are reshaping cancer center formulary decisions, explained panelists at PCOC.
Most community oncology practices now administer bispecific antibodies in-office, but reimbursement gaps remain a top barrier, a survey finds.
Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.
Switching MS patients to subcutaneous ocrelizumab cut chair time 82.8% and delivered $514,544 in 3-year value, a UVA analysis finds.
Topical ruxolitinib prescribing in Medicare Part D surged through 2024, but its cost per day runs 16 times higher than generic tacrolimus.
Baseline biopsies separated 16 patients who later developed hepatocellular carcinoma from 32 matched controls a median 6.1 years ahead.
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
2
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
3
Oncology Patients in Clinical Trials: A Health Care Cost Analysis
4
Surrogate End Points, Drug Costs Complicate Oncology Formularies
5